To prove that the efficacy and safety of 'Green Cross CELL* Immuncell-LC group' is superior to 'non-treatment group(Control group)' in patient undergone curative resection(PEIT, RFA or operation) for hepatocellular carcinoma in Korea

Multicenter, randomized, open-labeled phase 3 clinical trial.

Inclusion Criteria:

• Prior to the test, patient is fully explained about the purpose/ contents and characteristics of the testing medication, and the patient him(her)self, the guardian or the legal representative signed on written consent.

• The patient is more than 20 and less than 80 years old

• The patient is diagnosed as hepatocellular carcinoma by pathological/ radiological test and he (she) is in the stage of I or II. (refer to the attached file 10). Hepatocellular carcinoma should be shown by radiological test; on dynamic CT, dynamic MRI or on angiography.

• Child-Pugh Score should be less than 6 (refer to the attached file 7)

• No matter how the patient has been treated before, his (her) tumor should be totally removed by curative resection (PEIT, RFA or operation) in 12 weeks. (based on the agreement date for written consent) The tumor's removal should be perfectly confirmed by pathological or radiological test with the mentioned method in 3) at least 4 weeks later.

• ECOG Performance status (ECOG-PS) is less than 1 or equal to (refer to the exhibit 8)

• Patient's remaining life-time should be expected at least more than 3 months.

• Patient should meet below conditions by blood test, kidney and liver function test

  : Re-evaluation is possible during screening

• Leukocyte count is bigger than (3 multiply 109/L)

• Absolute Neutrophil Count (ANC) is bigger than or equal to 1,000/µL

• Hemoglobin is bigger than or equal to 8.5 g/dL

• Thrombocyte count is bigger than (5 multiply 1010/L)

• BUN and serum Creatinine is less than or equal to 1.5 multiply normal upper-limit

• No more disease abdominal extrahepatic transfer is confirmed by abdominal CT/ MRI

Exclusion Criteria:

• Hepatocellular carcinoma has been transferred by pathological/ radiological test (Stage III or Stage IV, refer to the exhibit 10)
• The carcinoma has been invaded to main portal vein or major branch hepatic vein
• Child-Pugh score is over 6
• Patient has serious problem with pulmonary function by sub- investigator's opinion
• Patient who has disease history of immune deficiency (which can be worse by immunotherapy) or auto-immune disease (ex. arthritis rheumatism, Burger's disease, multiple sclerosis and adolescent-occurred insulin dependent diabetes)
• Diagnosed as an immune deficiency patient
• Patient who has disease history of malignant tumor within 5 years before this clinical trial. (except for skin cancer, local prostate cancer or carcinoma in situ of the uterine cervix
• Patient who had anti-cancer medication before the clinical trial
• Patient who has serious disease in other organs after tumor resection.
• Patient has serious allergic-history by sub- investigator's opinion
• Patient has serious mental disease by sub- investigator's opinion
• Pregnant women, nursing mother or having intention of being pregnant during the clinical test
• Patient who participated in other clinical trial within 4 weeks before this clinical trial
• Patient who is incongruent to this clinical trial by sub- investigator's opinion.

A total of 230 eligible participants were assigned randomly to either the immunotherapy group(n=115) or the control group(n=115). Among these randomized patients, 226(114 in the immunotherapy group and 112 in the control group) were included in the efficacy analysis. 4 patients were excluded due to violation of the inclusion and exclusion criteria.

Adverse events were assessed from the time the patient provided written informed consent until the end of the study or drop-out, and until at least 30 days after the last dose of immunotherapy.